Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

Annapurna Therapeutics to Collaborate with Weill Cornell Medicine on Gene-Therapy Portfolio

Annapurna Therapeutics, formerly AAVLife, announces today a name change and an expanded scope in their gene therapy portfolio. As noted in the release, Annapurna is focused on treating the cardiomyopathy associated with FA and their current efforts include detailed cardiac testing in individuals with FA to help determine the best measurements for safety and efficacy in future trials and doing the necessary work in pre-clinical animals. For information on the cardiomyopathy studies at Weill Cornell please click here.   FARA looks forward to continued collaboration and support for Annapurna's efforts to advance gene therapy treatments for FA.

Press Release: http://www.businesswire.com/news/home/20160105005156/en/Annapurna-Therapeutics-Collaborate-Weill-Cornell-Medicine-Gene-Therapy


About the Author

Jen Farmer

Jen Farmer

Executive Director

SHARE

FacebookTwitterLinkedinShare on Google+
Event F.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News